Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
Condition(s):Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychotic Disorder NOSLast Updated:June 24, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychotic Disorder NOSLast Updated:June 24, 2019Terminated
Condition(s):Severe Alcoholic HepatitisLast Updated:December 4, 2023Not yet recruiting
Condition(s):Schizophrenia and Related Disorders; Immune Suppression; Psychosis; Cognitive ChangeLast Updated:August 1, 2022Terminated
Condition(s):SARS-CoV2 Infection; COVID-19Last Updated:March 9, 2023Withdrawn
Condition(s):Allergic Bronchopulmonary AspergillosisLast Updated:November 27, 2023Active, not recruiting
Condition(s):Pulmonary Disease, Chronic ObstructiveLast Updated:June 4, 2012Completed
Condition(s):Methylprednisolone; Intranasal Administration; Patients With an Active Multiple Sclerosis RelapseLast Updated:January 25, 2024Enrolling by invitation
Condition(s):Kawasaki DiseaseLast Updated:December 14, 2023Recruiting
Condition(s):B-cell Lymphomas (Phase 1); Advanced Solid Tumors (Phase 1); Diffuse Large B-cell Lymphoma (Phase 2); Follicular Lymphoma (Phase 2); Transformed Follicular Lymphoma; Primary Mediastinal Large B-Cell LymphomaLast Updated:August 4, 2023Completed
Condition(s):Rheumatoid ArthritisLast Updated:October 5, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.